CingulateCING -8.81%36 10-Year ROIIC % is -144.32 as of Dec. 2025. GuruFocus rates CING with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 1,108 Biotechnology companies, Cingulate ranks worse than 73.83% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Cingulate does not have enough data to calculate 10-Year ROIIC %.
Cingulate (NAS:CING) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cingulate 10-Year ROIIC % Related Terms
Cingulate 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Cingulate's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CING vs IMA, MCRB, PLRX: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, Cingulate's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cingulate 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cingulate's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cingulate's 10-Year ROIIC % falls into.
Cingulate's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -19.938 (Dec. 2025) - (Dec. 2015) )
/
( 10.055 (Dec. 2025) - (Dec. 2015) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cingulate (CING) has a 10-Year ROIIC % of -144.32 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Cingulate and its competitors. According to the industry distribution chart, Cingulate ranks #818 out of 1108 companies in the Biotechnology industry, placing it in the top 73.8%.
Is Cingulate's 10-Year ROIIC % too high?
Cingulate's current 10-Year ROIIC % is -144.32. Based on the distribution chart, Cingulate ranks #818 out of 1108 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cingulate has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's 10-Year ROIIC % compare to IMA and MCRB?
According to the Biotechnology industry distribution chart, Cingulate ranks #818 out of 1108 companies for 10-Year ROIIC %. This places Cingulate in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Cingulate and its competitors. Cingulate's current 10-Year ROIIC % is -144.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current 10-Year ROIIC % of -144.32. The current 10-Year ROIIC % is -144.32. Cingulate's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Cingulate (CING), the current 10-Year ROIIC % is -144.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
36GF Score
Get the complete analysis for CING
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CING has been successfully added to your 
